Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion
Go back to Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 54.70 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.70 | 52 Week High | $77.12 | |||
| Open | $54.70 | 52 Week Low | $49.03 | |||
| Day High | $54.70 | P/E | 35.52 | |||
| Day Low | $54.70 | EPS | $1.54 | |||
| Volume | 15,896 | |||||
